The Comfort of Companionship; Excess Weight, Excess Risk; Challenges of Rural Care

An oncologist reflects on the comforting effects of companionship during times of crisis and uncertainty. (JCO Art of Oncology)

Topline results from a phase II trial showed a 38% objective response rate in previously treated HER2-positive metastatic colorectal cancer with the combination of tucatinib (Tukysa) and trastuzumab, Seagen announced.

The FDA approved azacitidine for newly diagnosed juvenile myelomonocytic leukemia.

Servier Pharmaceuticals announced FDA approval of ivosidenib (Tibsovo) in combination with azacitidine for certain patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

Adding venetoclax (Venclexta) to dose-adjusted R-EPOCH therapy significantly increased complete response rate and survival in Richter’s syndrome. (Blood)

Excess weight during young and mid-adulthood was associated with worse survival in breast and colorectal cancer. (BMC Cancer)

Colonoscopy aided by artificial intelligence significantly improved detection of cancerous and precancerous polyps versus conventional colonoscopy. (NYU Langone Health, Digestive Disease Week)

The American Society of Clinical Oncology has updated its recommendations for diet, weight management, and physical activity during cancer treatment.

People living in rural areas continue to face major challenges in obtaining care for cancer and other chronic conditions. (Annals of Family Medicine)

A review of two common prostate cancer medications showed a stronger-than-expected association with diabetes and heart disease. (Michigan Medicine, Journal of the National Cancer Institute)